



Attorney's Docket No.: 07917-156001 / UMMC 01-46

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Krueger et al. Art Unit : 1645
Serial No. : 10/644,434 Examiner : Unknown
Filed : August 20, 2003
Title : ASSAY FOR THROMBOCYTOPENIA ASSOCIATED WITH
ADMINISTRATION OF PLATELET GPIIB-IIIa RECEPTOR ANTAGONIST

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Applicant submits the references listed on the attached form PTO-1449. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 07917-156001.

Respectfully submitted,

7-2-2004

Date:


Janice L. Kugler
Reg. No. 50,429


Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
20890052.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL


I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

7/2/04
Date of Deposit

Signature



Typed or Printed Name of Person Signing Certificate



Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 07917-156001	Application No. 10/644,434
Information Disclosure Statement by Applicant <small>(Use several sheets if necessary)</small> <small>(37 CFR §1.98(b))</small>		Applicant Krueger et al.			
		Filing Date August 20, 2003	Group Art Unit 1645		

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	5,246,832	Sep. 21, 1993	Michelson, et al.			
	A2	5,466,582	Nov. 14, 1995	Amiral			
	A3	5,763,201	Jun. 9, 1998	Tomer			
	A4	5,939,276	Aug. 17, 1999	Tomer			
	A5	5,972,717	Oct. 26, 1999	Aster et al.			
	A6	5,972,718	Oct. 26, 1999	Moghaddam et al.			
	A7	US 2002/0081624	Jun. 27, 2002	Billheimer et al.			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	B1						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C1	Bachelot et al., "Role of FcKRIIA Gene Polymorphism in Human Platelet Activation by Monoclonal Antibodies," Thrombosis and Haemostasis 74(6):1557-63 (1995)
	C2	Bednar et al., "Fibrinogen Receptor Antagonist-Induced Thrombocytopenia in Chimpanzee and Rhesus Monkey Associated With Preexisting Drug-Dependent Antibodies to Platelet Glycoprotein IIb/IIIa," Blood 94(2):587-599 (1999)
	C3	Berkowitz et al., "Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J. Am. Coll. Cardiol. 32(2):311-9 (1998)
	C4	Brandt et al., "On the Role of Platelet FcγRIIa Phenotype in Heparin-Induced Thrombocytopenia," Thrombosis and Haemostasis, 74(6):1564-1572 (1995)
	C5	Cannon et al., "Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial," Circulation 102(2):149-56 (2000)
	C6	Cazes et al., "Abciximab binding to glycoprotein IIb-IIa & protein tyrosine," Blood 93:9019-20 (1999)
	C7	Cines, "Glycoprotein IIb/IIIa antagonists: Potential induction and detection of drug-dependent antiplatelet antibodies," Amer. Heart J. 135(5 Pt. 2):S153-S159 (1998)
	C8	Fossati et al., "Fcγ receptors in autoimmune diseases," Eur. J. Clin. Invest. 31:821-31 (2001)
	C9	Frelinger et al., "Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation," Circulation 104(12):1374-9 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-156001	Application No. 10/644,434
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Krueger et al.		
		Filing Date August 20, 2003	Group Art Unit 1645	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C10	Furman et al., "Circulating monocyte-platelet aggregates are a more sensitive marker of platelet activation than P-selectin-positive platelets," Circulation 102, II-777 (2000)(Abstract)
	C11	Furman et al., "GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood," Thromb. Haemost. 84(3):492-8 (2000)
	C12	Honda et al., "Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca ²⁺ signaling," Blood 92(10):3675-83 (1998)
	C13	Khairy, et al., "A New Approach in the Study of the Molecular and Cellular Events Implicated in Heparin-induced Thrombocytopenia," Thromb Haemost 85:1090-6 (2001)
	C14	Lee et al., "A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry," Br. J. Haematol. 95(4):724-31 (1996)
	C15	McEver, 2002, "P-Selectin/PSGL-1 and Other Interactions Between Platelets, Leukocytes, and Endothelium," Platelets, (ed. by Alan D. Michelson), Ch. 9, Academic Press, New York 139-148
	C16	Michelson et al., "Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction," Circulation 104(13):1533-7 (2001)
	C17	O'Neill et al., "Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events," N. Eng. J. Med. 342(18):1316-24 (2000)
	C18	Peter et al., "Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors," Blood 92:3240-3249 (1998)
	C19	Peterson et al., "A recombinant soluble form of the integrin alpha IIb beta 3 (GPIIb-IIIa) assumes an active, ligand-binding conformation and is recognized by GPIIb-IIIa-specific monoclonal, allo-, auto-, and drug-dependent platelet antibodies," Blood 92(6):2053-63 (1998)
	C20	Stenberg et al., "A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation," J. Cell. Biol. 101(3):880-6 (1985)
	C21	Tcheng et al., "Readministration of abciximab: interim report of the ReoPro readministration registry," Am. Heart J. 138(1 Pt 2):S33-8 (1999)
	C22	The SYMPHONY Investigators, "Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes," Lancet 355(9201):337-45 (2000)
	C23	Tomiyama, "Response of human platelets to activating monoclonal antibodies: Importance of Fc gamma RII (CD32) phenotype and level of expression," Blood 80(9):2261-8 (1992)
	C24	van der Pol, 1998, "IgG receptor polymorphisms: risk factors for disease," Immunogenetics 48(3):222-32 (1998)
	C25	Warkentin, "Heparin-Induced Thrombocytopenia: A Ten-Year Retrospective," Annu. Rev. Med. 50:129-47 (1999)
	C26	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	